Stem cell therapy for Parkinson’s disease approved for Phase 1 trials
The U.S. Food and Drug Administration (FDA) has accepted an investigational new drug (IND) application for XS-411, a stem cell-based therapy developed by Xellsmart for Parkinson’s disease, clearing the way for a Phase 1 clinical trial. The company also received FDA approval for a similar stem cell therapy…